Results 11 to 20 of about 165,965 (304)

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.

Diabetes Care, 2022
OBJECTIVE To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS A nested case-control analysis was performed with use of the French national ...
J. Bezin, A. Gouverneur, M. Pénichon, C. Mathieu, R. Garrel, D. Hillaire-buys, A. Pariente, J. Faillie   +7 more
semanticscholar   +4 more sources

The Cardiovascular Effects of GLP‐1 Receptor Agonists [PDF]

Cardiovascular Therapeutics, 2010
SUMMARYGlucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety.
Okerson, Theodore, Chilton, Robert J
openaire   +2 more sources

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Molecular Metabolism, 2020
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short
M. Nauck, D. Quast, J. Wefers, J. Meier
semanticscholar   +1 more source

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials

BMC Endocrine Disorders, 2022
Background The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists are still controversial in the treatment of type 2 diabetes mellitus (T2DM) patients.
Jing Qin, Li Song
doaj   +1 more source

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

Frontiers in Endocrinology, 2022
The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds
Weiting Hu, Rui Song, Rui Cheng, Caihong Liu, Rui Guo, Wei Tang, Jie Zhang, Qian Zhao, Xing Li, Jing Liu   +9 more
doaj   +1 more source

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.

The Lancet, 2021
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as glucose lowering therapies, with additional benefits of weight loss and blood pressure reduction.
E. Brown, H. Heerspink, D. Cuthbertson, J. Wilding   +3 more
semanticscholar   +1 more source

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy

Frontiers in Endocrinology, 2022
AimsGlucagon‐like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists.
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee   +5 more
doaj   +1 more source

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Journal of Clinical Medicine, 2022
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs),
J. J. Gorgojo-Martínez, P. Mezquita-Raya, J. Carretero-Gómez, A. Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, M. D. García-de-Lucas, J. Núñez, J. Obaya, M. Soler, J. Górriz, M. Á. Rubio-Herrera   +11 more
semanticscholar   +1 more source

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

Frontiers in Synaptic Neuroscience, 2022
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission ...
Christian Hölscher
doaj   +1 more source

GLP-1 receptor agonists and conscious sedation. [PDF]

Interv Pain Med
This FactFinder presents a brief summary of the evidence and outlines recommendations regarding periprocedural management of patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) therapy undergoing elective pain procedures under conscious sedation.
Holder EK, Ni A, Levi D, International Pain and Spine Intervention Society's Patient Safety Committee.   +3 more
europepmc   +3 more sources